Results 1 to 10 of about 1,204 (125)

Clinical outcomes and safety of efgartigimod in Guillain–Barré syndrome: a retrospective observation study [PDF]

Frontiers in Immunology
BackgroundGuillain–Barré syndrome (GBS) is a severe acute autoimmune neuropathy with limited established therapeutic options. Efgartigimod, a human IgG antibody Fc fragment, can increase IgG degradation, which thus may be a promising therapeutic medicine
Yongli Tao, Ting Yang, Chenyang Jiang, Xue Wang, Liangliang Gu, Rui Zhang   +5 more
doaj   +2 more sources

Case Report: Efficacy of efgartigimod for autonomic dysfunction in patients with autoimmune glial fibrillary acidic protein astrocytopathy: a case series of 3 patients [PDF]

Frontiers in Immunology
IntroductionEfgartigimod can rapidly reduce serum IgG antibody levels and decrease antibody-mediated neuroinflammation and damage. It is primarily used to treat autoimmune diseases.
Huayi Ma, Bingying Xie, Yi Wu, Houshi Zhou, Feiyu Ma, Chuming Huang, Xiujun Zheng   +6 more
doaj   +2 more sources

Efficacy and safety of efgartigimod as an add-on therapy in patients with NMOSD and MOGAD at the acute attack phase [PDF]

Frontiers in Immunology
BackgroundNeuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein-associated disease (MOGAD) are autoimmune antibody-mediated diseases.
Weifan Yin, Weifan Yin, Shige Wang, Wei Lu, Wei Lu, Tianjiao Duan, Tianjiao Duan   +6 more
doaj   +2 more sources

Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study [PDF]

Frontiers in Immunology
ObjectiveTo analyze and compare the efficacy of ripertamab, rituximab, and efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on treatment response rates, relapse rates, drug safety, long-term clinical ...
Yutong Wu, Yue Zhou, Wanshuang Yin, Xiao Zhao, Lingxu Xu, Yinchao Su, Shuxin Wang, Siyu Li, Yue Wang, Chunmei Duan, Yiliang Fang, Zhaoyou Meng   +11 more
doaj   +2 more sources

Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis

Scientific Reports
Impending myasthenic crisis (IMC) is an emergent situation requiring aggressive management to prevent patients from developing myasthenic crisis (MC) in patients with myasthenia gravis (MG).
Jing Ma, Huiqiu Zhang, Junsen Zhao, Menghan Su, Yingna Feng, Xiaoli Yuan, Dan Liu, Xiaomin Pang, Rongjuan Zhao, Juan Wang, Weisong Duan, Xueli Chang, Junhong Guo, Wei Zhang   +13 more
exaly   +2 more sources

Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial [PDF]

Frontiers in Immunology
Background/objectiveEfgartigimod, a human immunoglobulin G1 (IgG1) antibody Fc fragment, reduces IgG levels through neonatal Fc receptor (FcRn) blockade.
Antoine E. Azar, John W. Sleasman, Sophie Steeland, Fien M. Verhamme, Kevin L. Winthrop   +4 more
doaj   +2 more sources

Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients

Frontiers in Neurology
BackgroundEfgartigimod was approved in Japan in January 2022 for the treatment of generalized myasthenia gravis (gMG), regardless of antibody status. This case series describes a real-world experience in Japan of efgartigimod treatment for gMG patients ...
Mitsuharu Ueda, Hironori Mizutani
exaly   +3 more sources

Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan [PDF]

Frontiers in Neurology
BackgroundEfgartigimod, a neonatal Fc receptor blocker, has received regulatory approval for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Japan in December 2024.AimsTo investigate the effectiveness and safety of ...
Tatsuya Imai, Kenichi Irie, Shinichiro Mori, Tomoaki Hoshino, Toshihiro Ide, Takahisa Tateishi   +5 more
doaj   +2 more sources

Immune checkpoint inhibitor-related kelch-like protein 11-IgG cerebellitis successfully treated with efgartigimod as rescue therapy: a case report [PDF]

Frontiers in Immunology
BackgroundWhile immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, neurological immune-related adverse events (n-irAEs) associated with these agents are increasingly recognized. However, kelch-like protein-11(KLHL11)-IgG cerebellitis
Yi-Xiao Li, Zhong-Mian Ma
doaj   +2 more sources

Rapid neurological recovery in Guillain-Barré syndrome treated with efgartigimod [PDF]

Scientific Reports
Efgartigimod, a neonatal Fc receptor inhibitor that accelerates IgG degradation, remains understudied in treatment of Guillain-Barré Syndrome (GBS). This study aimed to evaluate the efficacy and safety of efgartigimod in GBS patients.
Yifan Cheng, Wenyu Li, Siyu Xie, Shunyuan Guo, Chunrong Li, Manman Zhang, Yiqi Wang   +6 more
doaj   +2 more sources